<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34954931</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Electronic-Print">
        <Journal>
          <ISSN IssnType="Electronic">2191-0251</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>35</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>26</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of pediatric endocrinology &amp; metabolism : JPEM</Title>
          <ISOAbbreviation>J Pediatr Endocrinol Metab</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Weight management in youth with rapid-onset obesity with hypothalamic dysregulation, hypoventilation, autonomic dysregulation, and neural crest tumor (ROHHAD-NET): literature search and case report.</ArticleTitle>
        <Pagination>
          <StartPage>543</StartPage>
          <EndPage>548</EndPage>
          <MedlinePgn>543-548</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1515/jpem-2021-0600</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, autonomic dysregulation, and neural endocrine tumor (ROHHAD-NET) syndrome is a youth-onset constellation of symptoms including rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation. Despite growing understanding of the clinical classification of this syndrome there is limited investigation into treatment of the rapid-onset obesity which can be progressive and life-limiting. The purpose of this case report is to describe the clinical timeline and treatment of severe obesity in a patient with of ROHHAD-NET and propose recommendations for the treatment of associated obesity.</AbstractText>
          <AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">We present the case of a 10-year-old female with a clinical presentation consistent with ROHHAD-NET who achieved clinically meaningful weight loss with a combination of lifestyle modification and anti-obesity pharmacotherapies. We report on the use of three separate pharmacological agents and ultimately the referral for bariatric surgery.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Given that early-onset obesity and hypoventilation are life-limiting components of this condition, early recognition and treatment are essential to improve health outcomes.</AbstractText>
          <CopyrightInformation>© 2021 Walter de Gruyter GmbH, Berlin/Boston.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Marpuri</LastName>
            <ForeName>Ian</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0002-7282-8312</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Center for Diabetes, Endocrinology and Metabolism, Children's Hospital Los Angeles, Los Angeles, CA, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Keck School of Medicine of USC, Los Angeles, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ra</LastName>
            <ForeName>Esther</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Children's Hospital of Los Angeles, Los Angeles, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Naguib</LastName>
            <ForeName>Monica N</ForeName>
            <Initials>MN</Initials>
            <Identifier Source="ORCID">0000-0001-9036-8332</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Center for Diabetes, Endocrinology and Metabolism, Children's Hospital Los Angeles, Los Angeles, CA, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Keck School of Medicine of USC, Los Angeles, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vidmar</LastName>
            <ForeName>Alaina P</ForeName>
            <Initials>AP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Center for Diabetes, Endocrinology and Metabolism, Children's Hospital Los Angeles, Los Angeles, CA, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Keck School of Medicine of USC, Los Angeles, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>J Pediatr Endocrinol Metab</MedlineTA>
        <NlmUniqueID>9508900</NlmUniqueID>
        <ISSNLinking>0334-018X</ISSNLinking>
      </MedlineJournalInfo>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C536408">Neural crest tumor</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000310" MajorTopicYN="Y">Adrenal Gland Neoplasms</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001342" MajorTopicYN="Y">Autonomic Nervous System Diseases</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007027" MajorTopicYN="Y">Hypothalamic Diseases</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007040" MajorTopicYN="N">Hypoventilation</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">anti-obesity medications</Keyword>
        <Keyword MajorTopicYN="N">early-onset obesity</Keyword>
        <Keyword MajorTopicYN="N">rapid-onset obesity with hypothalamic dysfunction, hypoventilation, autonomic dysregulation, and neural endocrine tumor (ROHHAD-NET) syndrome</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>26</Day>
          <Hour>21</Hour>
          <Minute>7</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34954931</ArticleId>
        <ArticleId IdType="doi">10.1515/jpem-2021-0600</ArticleId>
        <ArticleId IdType="pii">jpem-2021-0600</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Harvengt, J, Gernay, C, Mastouri, M, Farhat, N, Lebrethon, MC, Seghaye, MC, et al.. ROHHAD(NET) syndrome: systematic review of the clinical timeline and recommendations for diagnosis and prognosis. J Clin Endocrinol Metab 2020;105:12–9. https://doi.org/10.1210/clinem/dgaa247.</Citation>
        </Reference>
        <Reference>
          <Citation>August, GP, Caprio, S, Fennoy, I, Freemark, M, Kaufman, FR, Lustig, RH, et al.. Prevention and treatment of pediatric obesity: an Endocrine Society clinical practice guideline based on expert opinion. J Clin Endocrinol Metabol 2008;93:23–37. https://doi.org/10.1210/jc.2007-2458.</Citation>
        </Reference>
        <Reference>
          <Citation>Barlow, SE, Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007;120(4 Suppl):S164–92. https://doi.org/10.1542/peds.2007-2329C.</Citation>
        </Reference>
        <Reference>
          <Citation>Cardel, MI, Atkinson, MA, Taveras, EM, Holm, JC, Kelly, AS. Obesity treatment among adolescents: a review of current evidence and future directions. JAMA Pediatr 2020;174:609–17. https://doi.org/10.1001/jamapediatrics.2020.0085.</Citation>
        </Reference>
        <Reference>
          <Citation>Pratt, JSA, Browne, A, Browne, NT, Bruzoni, M, Cohen, M, Desai, A, et al.. ASMBS pediatric metabolic and bariatric surgery guidelines, 2018. Surg Obes Relat Dis 2018;14:882–901. https://doi.org/10.1016/j.soard.2018.03.019.</Citation>
        </Reference>
        <Reference>
          <Citation>Armstrong, SC, Bolling, CF, Michalsky, MP, Reichard, KW, Section on Obesity, Section on Surgery. Pediatric metabolic and bariatric surgery: evidence, barriers, and best practices. Pediatrics 2019;144:2019–3223. https://doi.org/10.1542/peds.2019-3223.</Citation>
        </Reference>
        <Reference>
          <Citation>Lazea, C, Sur, L, Florea, M. Rohhad (Rapid-onset obesity with hypoventilation, hypothalamic dysfunction, autonomic dysregulation) syndrome—what every pediatrician should know about the etiopathogenesis, diagnosis and treatment: a review. Int J Gen Med 2021;14:319–26. https://doi.org/10.2147/ijgm.s293377.</Citation>
        </Reference>
        <Reference>
          <Citation>Fox, CK, Kelly, AS. Pharmacotherapy for severe obesity in children. Clin Pediatr 2015;54:1302. https://doi.org/10.1177/0009922815580407.</Citation>
        </Reference>
        <Reference>
          <Citation>Fox, CK, Marlatt, KL, Rudser, KD, Kelly, AS. Topiramate for weight reduction in adolescents with severe obesity. Clin Pediatr 2015;54:19–24. https://doi.org/10.1177/0009922814542481.</Citation>
        </Reference>
        <Reference>
          <Citation>Ryder, JR, Kaizer, A, Rudser, KD, Gross, A, Kelly, AS, Fox, CK. Effect of phentermine on weight reduction in a pediatric weight management clinic. Int J Obes 2017;41:90–3. https://doi.org/10.1038/ijo.2016.185.</Citation>
        </Reference>
        <Reference>
          <Citation>Kelly, AS, Rudser, KD, Nathan, BM, Fox, CK, Metzig, AM, Coombes, BJ, et al.. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial. JAMA Pediatr 2013;167:355–60. https://doi.org/10.1001/jamapediatrics.2013.1045.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
